ACETYLCYSTEINE IN THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- Authors: Gembltskaya T.1, Chermensky A.1
-
Affiliations:
- Acad. I.P. Pavlov Saint Petersburg State Medical University
- Issue: Vol 24, No 2 (2013)
- Pages: 37-40
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115666
- ID: 115666
Cite item
Open Access
Access granted
Abstract
The paper gives data on the mucolytic, antioxidative, and antitoxic properties of acetylcysteine and its use in chronic obstructive pulmonary disease.
Full Text
About the authors
T. Gembltskaya
Acad. I.P. Pavlov Saint Petersburg State Medical University
Email: mukoviscidoz_otd@mail.ru
A. Chermensky
Acad. I.P. Pavlov Saint Petersburg State Medical University
Email: mukoviscidoz_otd@mail.ru
References
- Гембицкая Т.Е., Черменский А.Г. Дифференцированный подход к лечению кашля / Справочник поликлинического врача. - 2008; 12: 4-7.
- Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. Под ред. А.С. Белевского / М.: Российское респираторное общество. -2012; 80 с.
- Мукоактивная терапия. Под ред. А.Г. Чучалина, А.С. Белевского / М.: Атмосфера, 2006. * По данным IMS за ноябрь 2012 г., в категории АТС3: ROSC (отхаркивающие средства).
- Симонова О.И. Детский кашель: вопросы патогенеза и терапии // Вопр. современной педиатрии. - 2012; 11 (3): 100-8.
- Фисенко В. О фармакологических свойствах и применении ацетилцистеина // Врач (спец. вып.). - 2007; 1-16.
- Benedetto de F., Aceto A., Dragani B. et al. Long-term oral N-acetylcysteine reduced exhaled hydrogen peroxide in stable COPD // Pulmonary Pharmacol. Ther. - 2005; 18 (1): 41-7.
- de Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm // Am. J. Respir. Crit. Care Med. - 2007; 175: 32-9.
- Decramer M., Rutten-van Molken M., Dekhuijzen et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial // Lancet. - 2005; 365 (9470): 1552-60.
- Dekhuijzen P. Acetylcysteine in the treatment of severe COPD // Ned. Tijdschr. Geneeskd. - 2006; 150: 1222-6.
- Fletcher C., Peto R. The natural history of chronic airflow obstruction // BMJ. - 1977; 1: 1645-8.
- Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2010 report is available on www.goldcopd.com
- Grandjean E., Berthet P., Ruffmann R., Leuenberger P. Costeffectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis // Pharmacol. Res. - 2000; 42: 39-50.
- Grandjean E., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral longterm N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials // Clin. Ther. - 2000; 22: 209-21.
- Guerra S., Sherrill D., Venker C. et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk // Thorax. - 2009; 64: 894900.
- Leeper K., Jones A., Tillotson G. The changing bacterial etiology of chronic obstructive pulmonary disease (COPD) // Chest. - 1997; 112; 21S.
- Mathers C., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030 // PLoS Med. - 2006; 3: 442.
- Poole P., Black P. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease // Cochrane Database Syst. Rev. - 2006; 19 (3): JulCD001287.
- Riise G., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N_acetylcysteine therapy? // Eur. Respir. J. - 1994; 7: 94-101.
- Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review // Eur. Respir. J. - 2000; 16: 253-62.
- Tashkin D., Celli B., Senn S. et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease // N. Engl. J. Med. - 2008; 359: 1543-54.
- Vestbo J., Prescott E., Lange P., Group at CCHS. Association between chronic mucus hypersecretion with FEV1 decline and COPD morbidity // Am. J. Respir. Crit. Care Med. - 1996; 153: 1530-5.
- Vestbo J. Epidemiological studies in mucus hypersecretion. In: D.J. Chadwick, J.A. Goode eds. Novartis foundation symposium 248: mucus hypersecration in respiratory disease. Malden: Wiley. - 2002. 277-82.
Supplementary files
